Michael Moore and Fritz Frickel join MISSION board
This article was originally published in Scrip
MISSION Therapeutics, a company focused on the discovery and development of modulators of the deubiquitylating enzyme family for the treatment of cancer, has appointed Dr Michael Moore executive chair and Dr Fritz Frickel non-executive director. Dr Moore has more than two decades of senior management experience in the biotech sector, most recently as CEO of Piramed. He is currently a non-executive director of several companies including PsiOxus Therapeutics. Dr Frickel is currently an independent advisor to venture capital firms, biotech start-ups and universities, having previously served as senior vice-president of R&D and acting CEO of Alantos.
You may also be interested in...
Almirall has launched its irritable bowel syndrome drug Constella (linaclotide) in six European countries, with several other launches planned for later this year.
Dermira, a dermatology-focused biotech, has raised $35m in a series B financing.
Clovis Oncology has raised its public offering, announced 11 June, from $170m to $240m.